On Wednesday evening, Moderna issued a press release announcing positive results from its Phase 3 cancer vaccine trial. By Thursday's close, the stock had spiked 177 percent — from roughly $63 to $174.38 — on volume of 185.1 million shares, which was 1,819 percent above its three-month average.
The trial in question is INTERPATH 001, a Phase 3 study testing Moderna's mRNA cancer vaccine intismeran in combination with Merck's Keytruda on 1,137 melanoma patients who'd had tumors surgically removed. According to the companies — and only the companies — the combination met its primary endpoint of recurrence-free survival and its secondary endpoint of distant metastasis-free survival, compared to Keytruda alone. Moderna's market cap went from $25 billion to $69 billion on those claims.
Forty-four billion dollars, created from a corporate announcement that hasn't been verified by a single independent scientist.
Charlotte Kupperwasser, a cancer biology professor at Tufts Medical School, put it plainly: "No data presented, no paper published — but apparently the stock market has already completed peer review."
Joseph Marine, the vice director for operations in Johns Hopkins Hospital's cardiology division, went further. "These corporations have learned how to play the medical-scientific establishment like a Stradivarius," he wrote, describing the playbook: press release, amplification by thought leaders, media feeding frenzy, stock price explosion. By the time published results arrive — if they arrive — the money's already been made.
This is the same company that claimed 94.5 percent effectiveness for its original COVID vaccine. The same company whose mRNA flu vaccine, mFluSiva, got FDA approval two weeks ago with data showing you'd need 5,000 shots to prevent a single hospitalization. Moderna timed that announcement for 10 p.m. on a Wednesday, and the stock popped 4 percent by morning.
Former FDA drug evaluation chief Tracy Beth Hoeg and FDA adviser Retsef Levi have both raised concerns about the pattern. Moderna's stock is up 357 percent year-to-date. That's not a pharmaceutical company. That's a press release engine with a lab attached.
The progressive health establishment will point out that INTERPATH 001 is a real trial with real patients and that the data will eventually be presented at a medical conference. Which is an interesting defense of a system where $44 billion in shareholder value gets created before anyone outside the company has seen a single data table. Pfizer quietly cancelled its own mRNA cancer trial in spring 2026. Nobody issued a press release about that.
NIH Director Jay Bhattacharya and HHS Secretary Robert F. Kennedy Jr. now oversee agencies that are supposed to evaluate these products. The question isn't whether mRNA cancer vaccines might eventually work — maybe they will. The question is whether a company should be able to add $44 billion to its market cap on claims that no independent researcher has verified, using the same announcement playbook it perfected during COVID.
The data will be published eventually, Moderna says. Merck Vice President of Oncology Jane Healy says they plan to submit to the FDA.
The stock price didn't wait for any of that. Maybe it should have.